Deals channel feed – Endpoints News

Deals channel feed

J&J gets a $30B Actelion buyout and a new partner as Clozel’s team spins out with the pipeline

9 years ago

Novartis’ biotech shopping spree stays focused on the low-budget specials of the day

9 years ago

A biotech billionaire grabs microcap GenVec and its gene vector tech in buyout

9 years ago

How Takeda won a $5.2B bidding war — against itself

9 years ago

Anthrax-targeted biodefense biotechs join forces in merger pact

9 years ago

Eli Lilly nabs CoLucid and a PhIII migraine drug in $960M buyout

9 years ago

Pfizer wants you. And you. And you. And you.

9 years ago

Takeda grabs Ariad, expands oncology portfolio in $5.2B buyout

9 years ago

Celgene antes up $55M, grabs option to buy the autoimmune upstart Anokion

9 years ago

Savara jumping to the NYSE in reverse merger with zombie biotech Mast

9 years ago

The forecast for biotech IPOs in 2017? Not nearly as hot as the industry would like

9 years ago

Getting to work on pipeline construction, new Ipsen CEO forges $1B deal to buy Merrimack’s struggling Onivyde

9 years ago

M&A inflation just pushed the average biopharma valuation to a scary new peak

9 years ago

Shire spins out mRNA group to RaNA, which is hatching plans to tackle cystic fibrosis in the clinic

9 years ago

Make that two biotech reverse mergers in one day

9 years ago

Crushed by a trial failure, Tokai hands the reins — and the stock listing — to Otic

9 years ago

Wait a second. J&J is back in the bidding for Actelion, elbowing Sanofi aside

9 years ago

Sumitomo Dainippon beefs up oncology pipeline with $780M Tolero buyout

9 years ago

Can Sanofi push a CVR on Actelion after the Lemtrada fiasco?

9 years ago

Allergan’s deal spree continues with $2.9B LifeCell buyout

9 years ago

Stiff-armed by a stubborn Actelion, J&J takes its check book and walks away, leaving an opening for Sanofi

9 years ago

Celgene buys Acetylon, keeps what it wants and spins the rest back out as Regenacy

9 years ago

Will J&J come up with a big enough treasure trove to win an Actelion buyout?

9 years ago

That EngMab buyout? Celgene agreed to pay up to $3B for BCMA-targeting drug

9 years ago

First page Previous page 113 114 115116117 Next page Last page